Article

ASCRS 2020: Updates, improved injection technique from Eyepoint Pharmaceuticals

Author(s):

Alex Delaney-Gesing
Conferences|ASCRS

Ophthalmology Times' Sheryl Stevenson speaks with Eyepoint Pharmaceuticals' President/CEO Nancy Lurker and Chief Medical Officer Dario Paggiarino, MD, on the company's latest developments and research ahead of the ASCRS 2020 virtual meeting.

 

See more ASCRS meeting coverage here

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
Steven R. Sarkisian, Jr., MD, ABO, speaks about glaucoma at the 2025 ASCRS annual meeting
Related Content
Ophthalmologists present data on perfluorohexyloctane eye drops
September 11th 2025

Ophthalmologists present data on perfluorohexyloctane eye drops

Evaluating safety, efficacy of TP03 for Demodex blepharitis treatment
September 11th 2025

Evaluating safety, efficacy of TP03 for Demodex blepharitis treatment

Q&A: Eva Kim, MD, on the value of EVO ICL for patients considering surgery
September 11th 2025

Q&A: Eva Kim, MD, on the value of EVO ICL for patients considering surgery

EyePod
September 11th 2025

ASCRS 2020: Assessing aberration of monofocal toric IOL with enhanced optic recovery, alignment

Ravi Patel, MD, shares ASCRS 2025 insights on enVista ASPIRE IOL user experience
September 11th 2025

Ravi Patel, MD, shares ASCRS 2025 insights on enVista ASPIRE IOL user experience

Monique Barbour, MD, highlights benefits of dropless protocol over traditional drops
September 11th 2025

Monique Barbour, MD, highlights benefits of dropless protocol over traditional drops

© 2025 MJH Life Sciences

All rights reserved.